These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Efficiency of study designs in diagnostic randomized clinical trials. Lu B; Gatsonis C Stat Med; 2013 Apr; 32(9):1451-66. PubMed ID: 23071073 [TBL] [Abstract][Full Text] [Related]
47. Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. Ventz S; Alexander BM; Parmigiani G; Gelber RD; Trippa L J Clin Oncol; 2017 Sep; 35(27):3160-3168. PubMed ID: 28530853 [TBL] [Abstract][Full Text] [Related]
48. Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints. Shan G J Biopharm Stat; 2020 Sep; 30(5):797-805. PubMed ID: 32129130 [TBL] [Abstract][Full Text] [Related]
49. Re-formulating Gehan's design as a flexible two-stage single-arm trial. Grayling MJ; Mander AP BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398 [TBL] [Abstract][Full Text] [Related]
50. Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family. Jiang W; Mahnken JD; He J; Mayo MS Pharm Stat; 2016 Nov; 15(6):459-470. PubMed ID: 27511063 [TBL] [Abstract][Full Text] [Related]
51. Designing phase II studies in cancer with time-to-event endpoints. Owzar K; Jung SH Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409 [TBL] [Abstract][Full Text] [Related]
53. Controlled multi-arm platform design using predictive probability. Hobbs BP; Chen N; Lee JJ Stat Methods Med Res; 2018 Jan; 27(1):65-78. PubMed ID: 26763586 [TBL] [Abstract][Full Text] [Related]
54. Optimal and minimax three-stage designs for phase II oncology clinical trials. Chen K; Shan M Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337 [TBL] [Abstract][Full Text] [Related]
55. Curtailed two-stage designs with two dependent binary endpoints. Chen CM; Chi Y Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348 [TBL] [Abstract][Full Text] [Related]
56. Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint. Zhao L; Taylor JM; Schuetze SM Stat Med; 2012 Jul; 31(17):1804-20. PubMed ID: 22359354 [TBL] [Abstract][Full Text] [Related]
57. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs. Colditz GA Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580 [TBL] [Abstract][Full Text] [Related]
58. Optimal two-stage design of single arm Phase II clinical trials based on median event time test. Park Y PLoS One; 2021; 16(2):e0246448. PubMed ID: 33556130 [TBL] [Abstract][Full Text] [Related]
59. Bayesian optimal phase II clinical trial design with time-to-event endpoint. Zhou H; Chen C; Sun L; Yuan Y Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679 [TBL] [Abstract][Full Text] [Related]
60. A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. Yin J; Qin R; Sargent DJ; Erlichman C; Shi Q J Biopharm Stat; 2018; 28(3):451-462. PubMed ID: 28448747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]